Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Prevalence of HLA-B*57 Serotype Associated with Hypersensitivity Reactions in the Treatment of HIV İnfection in the Turkish Population

Author(s): Muhammed Ali Kizmaz, Abdurrahman Simsek, Figen Aymak, Emin Halis Akalin, Haluk Barbaros Oral and Ferah Budak*

Volume 21, Issue 4, 2023

Published on: 15 September, 2023

Page: [254 - 258] Pages: 5

DOI: 10.2174/1570162X21666230731145350

Price: $65

Abstract

Objectives: The aim of our study is to reveal the prevalence of HLA-B*57 in the Turkish population and to provide new perspectives to physicians starting abacavir therapy in HIV patients.

Background: Abacavir, one of the drugs used to treat HIV infection, can cause hypersensitivity reactions in some patients. These hypersensitivity reactions have been shown to be associated with the HLA-B*57:01 allele. High-resolution HLA-B*57:01 scanning has a time and cost disadvantage compared with low-resolution HLA-B*57 scanning. Before starting abacavir treatment, we will discuss whether high-resolution scanning is more beneficial in individuals who are positive on HLAB* 57 screening. This is the study with the largest cohort to investigate the prevalence of HLA-B*57 in Turkey.

Methods: The results of 25 thousand 318 people who applied to Bursa Uludağ University Faculty of Medicine, Department of Immunology for HLA-B* typing were scanned.

Results: In our study, the HLA-B*57 serotype was detected in 827 (3.3%) individuals.

Conclusion: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.

Keywords: Abacavir, hypersensitivity, HLA, infection, HIV, prevalence.

« Previous Next »
Graphical Abstract

[1]
Rhodes T, Simic M. Transition and the HIV risk environment. BMJ 2005; 331(7510): 220-3.
[http://dx.doi.org/10.1136/bmj.331.7510.220] [PMID: 16037463]
[2]
World Health Organization (WHO) Clinical Guidelines: HIV Diagnosis. 2021. Available at: https://www.who.int/health-topics/hiv-aids (Accesed 20 December 2021)
[3]
Fauci AS, Lane HC. Four decades of HIV/AIDS: Much accomplished, much to do. N Engl J Med 2020; 383(1): 1-4.
[http://dx.doi.org/10.1056/NEJMp1916753] [PMID: 32609976]
[4]
Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368(3): 218-30.
[http://dx.doi.org/10.1056/NEJMoa1110187] [PMID: 23323898]
[5]
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382(9903): 1525-33.
[http://dx.doi.org/10.1016/S0140-6736(13)61809-7] [PMID: 24152939]
[6]
Dean L. Abacavir therapy and HLA-B*57:01 genotype. In: Medical Genetics Summaries. Bethesda, MD: National Center for Biotechnology Information 2018.
[7]
Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 1999; 43(3): 603-8.
[http://dx.doi.org/10.1128/AAC.43.3.603] [PMID: 10049274]
[8]
Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6): 568-79.
[http://dx.doi.org/10.1056/NEJMoa0706135] [PMID: 18256392]
[9]
Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359(9308): 727-32.
[http://dx.doi.org/10.1016/S0140-6736(02)07873-X] [PMID: 11888582]
[10]
Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359(9312): 1121-2.
[http://dx.doi.org/10.1016/S0140-6736(02)08158-8] [PMID: 11943262]
[11]
Martin MA, Hoffman JM, Freimuth RR, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 Update. Clin Pharmacol Ther 2014; 95(5): 499-500.
[http://dx.doi.org/10.1038/clpt.2014.38] [PMID: 24561393]
[12]
Park WB, Choe PG, Song KH, et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009; 48(3): 365-7.
[http://dx.doi.org/10.1086/595890] [PMID: 19115972]
[13]
Araújo C, Carvalho CV, Souza Freire ME, et al. Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-1 infected individuals in Brazil. Open J Genet 2014; 4(1): 56-62.
[http://dx.doi.org/10.4236/ojgen.2014.41008]
[14]
Zhang H, Zhang T, Zhao H, et al. Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: A prospective epidemiological investigation. AIDS Res Ther 2015; 12(1): 28.
[http://dx.doi.org/10.1186/s12981-015-0064-9] [PMID: 26300948]
[15]
Baniasadi S, Shokouhi SB, Tabarsi P, et al. Prevalence of HLA-B*57:01and its relationship with abacavir hypersensitivity reaction in Iranian HIV- infected patients. Tanaffos 2016; 15(1): 48-52.
[PMID: 27403179]
[16]
Arrizabalaga J, Rodriguez-Alcántara F, Castañer JL, et al. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials 2009; 10(1): 48-51.
[http://dx.doi.org/10.1310/hct1001-48] [PMID: 19362996]
[17]
Poggi H, Vera A, Lagos M, Solari S, Rodríguez PL, Pérez CM. HLA-B*5701 frequency in chilean HIV-infected patients and in general population. Braz J Infect Dis 2010; 14(5): 510-2.
[PMID: 21221482]
[18]
Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 2007; 60(3): 599-604.
[http://dx.doi.org/10.1093/jac/dkm243] [PMID: 17631508]
[19]
Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: A single centre experience. AIDS 2007; 21(18): 2533-4.
[http://dx.doi.org/10.1097/QAD.0b013e328273bc07] [PMID: 18025891]
[20]
Joint United Nations Programme on HIV and AIDS (UNAIDS) Global HIV & AIDS statistics— Fact sheet. 2022. Available at: https://www.unaids.org/en/resources/fact-sheet (Accesed 23.11.2022)
[21]
Republic of Turkey Ministry of Health, General Directorate of Public Health, Department of Communicable Diseases HIV-AIDS statistics. 2022. Available at: https://hsgm.saglik.gov.tr/tr/bulasici-hastaliklar/hiv-aids/hiv-aids-liste/hiv-aids-istatislik.html (Accessed 23.11.2022)
[22]
Mete B. Antiretroviral therapy. J Inf Dis-Special Topics 2016; 9(1): 101-7.

Rights & Permissions Print Cite
Article Metrics
18
2
© 2024 Bentham Science Publishers | Privacy Policy